Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Clinigen to take back US rights to cancer drugs

Wed 15 May 2019 12:43 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Aim\'s Clinigen Group is taking back control of two oncology drugs from US partner Cumberland Pharmaceuticals.

Cumberland had been marketing, promoting and distributing Ethyol and Totect, which are intended to reduce toxic side-effects of chemotherapy and radiation, in the US since 2015.

However, in April, Clinigen acquired the US rights to another cancer treatment, Proleukin, from Novartis, and is using the acquisition to expand its presence in the lucrative American market.

Cumberland and Clinigen have therefore mutually agreed for the US rights to Ethyol and Totect to revert to the London-listed firm.

Shaun Chilton, chief executive of Clinigen, said: \"Proleukin acted as a catalyst to create our own commercial medicines infrastructure in the US. Taking back direct control of Ethyol and Totect was the next part of this strategy.

\"Cumberland\'s team has done a substantial amount of work during the strategic alliance to reintroduce Ethyol and Totect into the US. This has enabled the provision of an important source of medicines to healthcare professionals and their patients. We have worked well with the Cumberland team and expect the transition to be relatively smooth one.\"

The transfer is due to take effect by the fourth quarter of 2019, with the benefit beginning to be recognised in 2021. Clinigen said there would be \"limited financial impact\" on the 2020 full-year.

In a note, Peel Hunt said: \"This transition was expected since Clinigen acquired marketing infrastructure with the US rights to Proleukin, and had previously suggested it would look to take over responsibility for the other components of the commercial medicines marketing activity in the US.\"

Shares in Clinigen were trading 2% higher at 1,009p by 1415 BST.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.

    More company news from ShareCast